Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
1
20%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Active, not recruiting4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting480%
completed120%

Recent Activity

4 active trials
Showing 5 of 5
active_not_recruitingphase_2

Dostarlimab and Cobolimab in Advanced Cervical Cancer

NCT06238635
active_not_recruitingphase_1

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT06521567
active_not_recruitingphase_1

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

NCT04446351
active_not_recruitingphase_3

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976
completedphase_1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

NCT02723955

Clinical Trials (5)

Showing 5 of 5 trials
NCT06238635Phase 2

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Active Not Recruiting
NCT06521567Phase 1

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Active Not Recruiting
NCT04446351Phase 1

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT04655976Phase 3

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active Not Recruiting
NCT02723955Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5